Get the full INFEX Therapeutics company profile
Access contacts, investors, buying signals & more
INFEX Therapeutics, the biotech firm based at Alderley Park in the North West of England, has closed a $5.9M seed round to accelerate its work on life-threatening infections.
The capital infusion, led by investor Jon Moulton, will fuel the company's expansion beyond pandemic infections. INFEX plans to develop a broader portfolio of new therapies for critical priority infectious diseases, aiming to address unmet patient needs by bringing innovative drugs into clinical trials.
馃挔Today's Insider news from across the UK 鈻笍SW - Long-established streetwear and skateboard retailer Route One transitions to employee ownership https://lnkd.in/eSyY4jFi 鈻笍W Mids - Report sheds light on job-saving deal for Royal Warrant-holding pottery business https://lnkd.
in/e7FwZu6j 鈻笍Yrks - Laboratory simulator business Envoke targets Asia-Pacific with 拢1.6m funding - "well positioned to reach out to an even wider international audience" https://lnkd.in/e-wKdRXM 鈻笍NW - Biotech company INFEX Therapeutics secures 拢4.3m in funding to advance treatments pipeline - investment led by prominent venture capitalist Jon Moulton https://lnkd.in/eq74yPk5 鈻笍E Mids - Pre-pa
Beta Bugs Limited
Beta Bugs is a cutting edge biotechnology company that produces enhanced insect strains for the growing insect farming industry. The domesticated, optimised strains we produce provide benefits at all levels of the production chain ensuring the industry is both more profitable and sustainable. We accelerate the evolution of the organisms to create traits that ensure greatly superior final products.
$1.1M Seed
today
Metal Morph
Water treatment plants are urban mines - critical minerals hiding in plain sight. We're building the infrastructure to recover them. We recover critical metals and chemicals from industrial waste streams and return them to supply chains - reducing carbon, improving resilience, and lowering cost. 89% lower carbon emissions. 90% recovery. 26% lower cost.
$944.2K Pre-seed
today
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 |  NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  DIMENSION United States | Seed | $1.6M | today |
| 2 |  Dimension Studios United States | Seed | $1.6M | today |
Skinscanner.gg
Skinscanner (formerly MaestroAI) is building the Skyscanner of the tradable in-game assets industry. Operating within a $62bn fragmented ecosystem, Skinscanner acts as the bridge between players & marketplaces, removing the hassle of hunting for the best deals, so gamers can focus on what really matters: gaming.
$404.7K Pre-seed
today
| $7.2B |
| 1y ago |
| 3 |  Illumina United States | Unknown | $7.1B | 1y ago |
| 4 |  GRAIL United States | Unknown | $7.1B | 1y ago |
| 5 |  RemeGen Biosciences United States | Grant | $5.6B | 7mo ago |
| 3 |
 Demand AI United States |
| Seed |
| $6.3M |
| today |
| 4 | Beta Bugs Limited United Kingdom | Seed | $1.1M | today |
| 5 |  AGent Energy United States | Seed | $11.0M | today |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
Jon Moulton
Reach INFEX Therapeutics's investors directly from your dashboard.
Start free trialColm L.
Chief Clinical Officer & Chair of Clinical Development Committee
Victoria S.
Chief Scientific Officer
Unlock 8 more key decision-makers at INFEX Therapeutics with verified emails and LinkedIn.
Start free trial
Baymatob
Recently received
Nutrivert
Recently received
Novel Microdevices
Recently received
